A groundbreaking study combining laboratory experiments with human patient data has uncovered a troubling paradox: glucosamine supplements, trusted by millions for joint health, may accelerate cognitive decline specifically in people with Alzheimer’s disease, while remaining safe for healthy individuals.
Researchers conducted controlled animal studies examining glucosamine’s effects on brain function across different neurological states. In healthy brain tissue, glucosamine appeared neutral or potentially protective. However, in animal models of neurodegeneration, the supplement was associated with worsened memory impairment and faster cognitive decline. Researchers hypothesize the mechanism may involve altered glucose metabolism in diseased neural tissue.
These findings raise critical questions about supplement safety in vulnerable populations. With millions of seniors taking glucosamine globally, the research highlights an urgent need for disease-specific evaluation of nutritional interventions before they reach patients with existing neurodegenerative conditions.
Read the full article on GMJ Newsroom.
Was this article helpful?
